Adjusted earnings per share were $3.73, a 9.1% increase year-over-year.
Adjusted gross margin was 59.7%, a 110 basis point decrease year-over-year due to cost inflation, logistics, and unfavorable product mix, partially offset by foreign exchange.
Adjusted operating margin was 26.9%, a 20 basis point increase year-over-year, better than expected due to operating expense control and FX benefits.
Cash, cash equivalents and restricted cash were $283.9 million at quarter end, down from $327.7 million at year-end 2024.
Cash flow from operations for 6 months was $81.2 million, down from $204.5 million prior period, mainly due to working capital changes and acquisition-related costs.
Net leverage was approximately 1.8x at quarter end and 2.6x pro forma for the Vascular Intervention acquisition.
Second quarter revenues were $780.9 million, an increase of 4.2% year-over-year on a GAAP basis and up 1% on an adjusted constant currency basis, exceeding the high end of previous guidance.
Dafinchi